
WHAT IS CLAIMED IS:

[Claim 1]. A crystalline anhydrate form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, or 23.6° 2θ ± 0.2° 2θ, Form B.

[Claim 2]. The crystalline form of claim 1, characterized by an XRPD pattern comprising four or more peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, or 23.6° 2θ ± 0.2° 2θ.

[Claim 3]. The crystalline form of claims 1 or 2, characterized by an XRPD pattern comprising five or more peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, or 23.6° 2θ ± 0.2° 2θ.

[Claim 4]. The crystalline form of any one of claims 1 to 3, characterized by an XRPD pattern comprising peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, and 23.6° 2θ ± 0.2° 2θ.

[Claim 5]. The crystalline form of any one of claims 1 to 4, characterized by an XRPD pattern comprising peaks at 9.8, 10.4, 11.2, 11.8, 13.4, 13.7, 14.8, 15.8, 16.2, 16.6, 16.7, 17.0, 17.3, 17.7, 18.0, 19.0, 19.6, 20.3, 20.5, 20.8, 21.0, 21.3, 22.0, 22.3, 22.7, 23.6, 23.8, 24.4, 25.4, 25.6, 25.7, 26.3, 28.1, 28.7, and 37.2° 2θ ± 0.2° 2θ.

[Claim 6]. The crystalline form of any one of claims 1 to 5, characterized by an XRPD pattern substantially as shown in FIG. 1.

[Claim 7]. The crystalline form of any one of claims 1 to 6, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 255°C.

[Claim 8]. The crystalline form of any one of claims 1 to 7, characterized by a DSC thermogram substantially as shown in FIG. 3.

[Claim 9]. A pharmaceutical composition comprising a crystalline form of any one of claims 1 to 8, and one or more pharmaceutically acceptable excipients.

[Claim 10]. The pharmaceutical composition of claim 9, further comprising one or more additional therapeutic agents.

[Claim 11]. Use of a crystalline form of any one of claims 1 to 8, or a pharmaceutical composition of claims 9 or 10, in the preparation of a medicament for use in treating fatty liver disease.

[Claim 12]. The use of claim 11, wherein the fatty liver disease is alcohol related liver disease (ARLD) or nonalcoholic fatty liver disease (NAFLD).

[Claim 13]. The use of claim 12, wherein the alcohol related liver disease is alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH) or alcoholic cirrhosis.

[Claim 14]. The use of claims 11 or 12, wherein the nonalcoholic fatty liver disease is nonalcoholic steatohepatitis (NASH) or nonalcoholic cirrhosis.

[Claim 15]. The use of claim 14, wherein the nonalcoholic fatty liver disease is nonalcoholic steatohepatitis.

[Claim 16]. Use of the crystalline form of any one of claims 1 to 8, or a pharmaceutical composition of claims 9 or 10, in the preparation of a medicament for treating antipsychotic induced weight gain.